 |
| Fig 1: Ezetimibe |
Ezetimibe is the first of a novel class of drugs for the treatment of hyperlipidaemia whose main action is to specifically prevent cholesterol absorption from the small intestine. Typically it reduces LDL-cholesterol by approximately 20%, triglycerides by up to 5% and raises HDL-cholesterol by approximately 5%. It does not inhibit the absorption of fat-soluble vitamins unlike the anion-exchange resins (e.g. colestyramine). Ezetimibe can be safely co-administered with statins and is currently licensed for use in combination with a statin in patients who fail to reach desired lipid profiles or as monotherapy in patients intolerant to a statin. There is no increased risk of myopathy with ezetimibe prescription.
Source: Fig1,
No comments:
Post a Comment